| Name | Title | Contact Details |
|---|
Our mission is to improve the health and wellbeing of North Carolinians and others whom we serve. We accomplish this by providing leadership and excellence in the interrelated areas of patient care, education, and research. We strive to promote faculty, staff and learner development in a diverse, respectful environment where our colleagues demonstrate professionalism, enhance learning, and create personal and professional sustainability. We optimize our partnership with the UNC Health Care System through close collaboration and a commitment to service.
DxNA is a St George, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Poretta and Orr, Inc. is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Management Associates is a for-profit corporation which operates hospitals and other health care facilities in the southern United States. It is headquartered at 5811 Pelican Bay Blvd. in North Naples, Florida. Its current CEO is Gary D. Newsome. Serving on the board of directors are William Schoen, Pascal Goldschmidt, Donald Kiernan, William Steere, Vicki O'Meara, Robert Knox, Kent Dauten and Randolph W. Westerfield. Health Management Associates (HMA) is an organization that provides people, processes, capital, and subject matter expertise to hospitals and physician practices per their individual needs or governing requirements (1). Additional functions that HMA provides to hospitals and provider groups are to invest capital for renewal of hospital facilities, recruiting of physicians to expand community resources or hospital services, and promote the use standardized best practices throughout HMA facilities.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.